Rohini Patil; Kamal Shah; Deepak Bhosle
Abstract
Background: Evaluation of the impact of stress on glycaemic control in hospitalized type-2 diabetes (T2DM) patients with coronavirus disease (COVID-19).Methods: In this retrospective study conducted at a single centre in Maharashtra from May to July 2020 on hospitalized COVID-19 patients with T2DM who ...
Read More
Background: Evaluation of the impact of stress on glycaemic control in hospitalized type-2 diabetes (T2DM) patients with coronavirus disease (COVID-19).Methods: In this retrospective study conducted at a single centre in Maharashtra from May to July 2020 on hospitalized COVID-19 patients with T2DM who reported having stress of pandemic; they were selected using purposive sampling. DASS-12 stress sub-scale was used to estimate the severity of their stress. Fasting blood glucose (FBG) and post-prandial blood glucose (PPBG) before admission and at the time of discharge were compared.Results: One hundred and ninety-nine patients (mean age 54 years; 61.30% females) were included. Mean±SD FBG before admission was 168.4±30.6 mg/dl which increased to 195.9±28.8 mg/dl at the time of discharge (P<0.001). Also, Mean±SD PPBG before admission was 312±62.3 mg/dl which increased to 351.6±61.9 mg/dl (P<0.001). A total of 73 (36.7%) participants had perceived stress. Moderate and severe/extremely severe stress was found in 44 (27.1%) and 19 (9.6%) patients, respectively. A significant difference was observed in the mean FBG before and during discharge in patients who had no stress and those with moderate stress (P<0.001). There was no difference in FBG in patients with severe/extremely severe stress (P=0.43). Similar observations were seen for PPBG (no stress P<0.001; moderate stress P<0.001; severe/extremely severe stress P=0.06).Conclusion: There was a rise in the glucose level in T2DM patients discharged after COVID-19 treatment. The increase was significant in T2DM without stress and those with moderate stress. In addition to traditional treatment, measures for psychological stress control should also be taken for such patients.
Zohreh Mazloom; Mohammad Hossein Dabbaghmanesh; Mahsa Moazen; Sara Bagheri
Volume 3, Issue 4 , October 2015, , Pages 146-152
Abstract
Background: Use of glucosamine as an alternative treatment for osteoarthritis is becoming more frequent, including in those who have diabetes at the same time. The results from in vitro and animal studies propose that glucosamine may inversely affect glucose metabolism. However, the recommended dose ...
Read More
Background: Use of glucosamine as an alternative treatment for osteoarthritis is becoming more frequent, including in those who have diabetes at the same time. The results from in vitro and animal studies propose that glucosamine may inversely affect glucose metabolism. However, the recommended dose of oral glucosamine in healthy people or diabetics did not have such effects consistently. The aim of the present study was to assess the effect of glucosamine on glycemic control and insulin resistance in type 2 diabetic patients. Methods: Fifty-four patients with type 2 diabetes participated in this randomized, double-blind, placebo-controlled study. The participants were assigned to receive 1500 mg glucosamine hydrochloride or placebo for 12 weeks. After determining their baseline characteristics, body mass index and dietary intake components, fasting blood glucose and fasting insulin were measured at weeks of 0, 8, and 12. Indices of insulin function including quantitative insulin sensitivity check index (QUICKI) and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated by specific formulas. Independent t-test and general linear model repeated measures were used to analyze the data. Results: In the glucosamine group, the means of fasting blood glucose and insulin were 107.31±24.07 mg/dl and 8.75±4.37 μu/ ml, respectively at baseline, which reached 112.38±31.50 and 9.10±4.17 at week 12. In the placebo group, the mean for fasting blood glucose and insulin were 103.84±24.15 and 9.79±4.02 at the beginning of the study, which reached to 111.40±26.43 and 8.58±3.68 at week 12. The results showed that there were no significant differences in fasting blood glucose, insulin, HOMA-IR and QUICKI indices at all the studied time points (weeks of 0, 8 and 12) within or between the groups. Conclusion: Twelve weeks of a normal recommended dose of glucosamine supplements may not have adverse effects on glycemic control and insulin resistance in type 2 diabetic patients.Trial registration number: IRCT2014031811785N2.
